Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582608 · ClinicalTrials.gov registry record · NA
Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00582608: Clinical Trial NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00582608 is a NA study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00582608, a NA study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether the monoclonal antibody 8H9 is useful in finding tumors in your body. Antibodies are protein found naturally in blood. They can fasten themselves to bacteria and viruses. They can stimulate white cells and blood proteins to kill tumors. The antibody 8H9 was made from mouse white cells. The white cells that secrete this antibody have been made to live for ever. They manufacture large amounts of 8H9 for patient use. Although other monoclonal antibodies have been safely tested in people, the antibody 8H9 has never been given to a human patient.
Interventions
- DRUG 131I-8H9
- DRUG 8H9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2001-10 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582608
The ClinicalTrials.gov registry entry for NCT00582608 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 131I-8H9 is the first listed.
NCT00582608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582608 about?
NCT00582608 is a clinical study titled "Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9". The purpose of this study is to find out whether the monoclonal antibody 8H9 is useful in finding tumors in your body. Antibodies are protein found naturally in blood. They can fasten themselves to bacteria and viruses. They can stimulate white cells and blood proteins to kill tumors. The antibody 8...
What is the current status of trial NCT00582608?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2001-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00582608?
The interventions under investigation include: 131I-8H9 (DRUG), 8H9 (DRUG).
Who is sponsoring clinical trial NCT00582608?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.